TIDMSLN
RNS Number : 5154V
Silence Therapeutics PLC
15 April 2021
Silence Therapeutics Announces Publication in Cardiovascular
Research Highlighting the Emerging Potential of RNA Therapeutics in
Preventing Lipoprotein(a)-Mediated Cardiovascular Disease
- High Lipoprotein(a) is a genetically determined cardiovascular
risk factor affecting around 20% of the world's population
15 April 2021
LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN ("
Silence " or " the Company "), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced a new review
publication on the prevention of cardiovascular disease linked to
high lipoprotein(a) - Lp(a) - levels in the latest issue of
Cardiovascular Research, linked here .
The paper, authored by senior medical and scientific experts
from both Silence and leading cardiology centers, explores the
emerging potential of RNA interference (RNAi) therapeutics in
lowering elevated levels of Lp(a), which are associated with higher
cardiovascular risk compared to the general population. Published
in the European Society of Cardiology's research journal, the paper
provides a timely assessment of current approaches to managing high
Lp(a), which is estimated to affect around 20% of the world's
population or a staggering 1.4 billion people globally.
Giles Campion, MD, EVP, Head of R&D and Chief Medical
Officer of Silence Therapeutics said: "There is a growing body of
evidence demonstrating high Lp(a) as a key predeterminant of
cardiovascular disease, including premature heart attack and
stroke. Unlike high cholesterol, which is a modifiable risk factor,
high Lp(a) is a genetic risk factor that you cannot manage through
diet or lifestyle changes. When considering a potential long-term
preventative treatment for a large population, Lp(a)-lowering
therapy must be safe, effective, well tolerated and conveniently
administered. Our review explores the promising potential of RNAi
therapies to fit that profile and address a major unmet need in
cardiovascular disease."
Silence is evaluating its wholly owned lead RNAi candidate,
SLN360, for the treatment of high Lp(a) levels in the ongoing
global APOLLO Phase 1 trial. In pre-clinical studies to date,
SLN360 has demonstrated sustained and deep reduction of Lp(a) serum
levels (>90%) with an excellent safety profile. The Company
anticipates reporting data in the single-ascending dose portion of
the study in the second half of 2021. More information on the study
can be found here .
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20 7597
Broker) 5970
Daniel Adams/Gary Clarence
European PR Tel: +44 (0) 20 3709
Consilium Strategic Communications 5700
Mary-Jane Elliott/ Angela Gray / Chris
Welsh
silencetherapeutics@consilium-comms.com
About SLN360
Silence's wholly owned lead product candidate, SLN360, is a gene
'silencing' therapy - one that is designed to temporarily block a
specific gene's message that would otherwise trigger an unwanted
effect. In this case, it aims to 'silence' LPA, a gene that tells
the body to make a specific protein that is only found in Lp(a). By
silencing the LPA gene, the levels of Lp(a) are lowered, which in
turn is expected to lower the risk of heart diseases, heart attacks
and strokes.
About Lipoprotein(a)
Lipoprotein(a), known as Lp(a) for short, is a particle made by
the liver, which consists of cholesterol, fats and proteins. Most
people have some Lp(a) in their body, but about 1 in 5 people have
high levels of Lp(a), because of a specific gene variation in their
DNA. Most people are unaware if they have elevated Lp(a). People
living with elevated Lp(a) have a higher risk of developing early
heart disease, heart attacks and strokes. Most standard cholesterol
tests do not currently include screening for Lp(a). Current
medicines that are used to lower other lipid levels in the blood do
not have a meaningful effect on Lp(a) and are less effective
overall in people with high levels of Lp(a).
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary mRNAi GOLD(TM) platform can be
used to create siRNAs that precisely target and silence
disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address iron
loading anemias. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Takeda, among others. For more information,
please visit https://www.silence-therapeutics.com/ .
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements, including with respect to the Company's clinical
development timeline and commercial prospects. These
forward-looking statements are not historical facts but rather are
based on the Company's current expectations, estimates, and
projections about its industry; its beliefs; and assumptions. Words
such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,'
'seeks,' 'estimates,' and similar expressions are intended to
identify forward-looking statements. These statements are not
guarantees of future performance and are subject to known and
unknown risks, uncertainties, and other factors, some of which are
beyond the Company's control, are difficult to predict, and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements, including the
potential impact of COVID-19 on the Company's clinical development
and regulatory timelines and plans. The Company cautions security
holders and prospective security holders not to place undue
reliance on these forward-looking statements, which reflect the
view of the Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESEAELLFEXFEAA
(END) Dow Jones Newswires
April 15, 2021 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024